In vivo experiments further showed that BPQD-RMNV-mediated PTT combined with anti-PD-1 antibody treatment significantly promoted the infiltration of CD8+ T cells into tumor sites, inhibited CD8+ T cell depletion at tumor sites, increased the anti-tumor activity of CD8+ T cells, and significantly inhibited tumor cell growth at residual and metastatic tumor sites. The gene discussed is PDCD1; the disease is neoplasm.